Play all audios:
ABSTRACT We retrospectively reviewed the impact of impaired renal function (eGFR < 45 ml/min/SA) on post-transplant outcomes in patients receiving ASCT for AL amyloidosis. Patients were
grouped into two cohorts, those with normal renal function (NRF) eGFR ≥ 45 ml/min (_n_ = 568) and those with impaired renal function (IRF) eGFR < 45 ml/min (_n_ = 87). Patients with IRF
had higher renal stage (>Stage 1: 100% IRF vs 37% NRF, _p_ < 0.0001) and the majority received conditioning with melphalan <200 mg/m2 (70% IRF vs 21% NRF, _p_ < 0.0001).
Forty-four patients (6.7%) required dialysis within 100 days of ASCT. Renal stage predicted for dialysis institution within 100 days of ASCT (3% Stage I vs 10% Stage II vs 22% Stage III, _p_
< 0.0001). Dialysis within 100 days was higher in the IRF cohort (16% for IRF cohort vs 6% for NRF cohort, _p_ = 0.0007. Patients with impaired renal function were more likely to be
admitted to hospital (80% IRF vs 70% NRF, _p_ = 0.03). The 100-day mortality was higher in the IRF cohort (14% IRF cohort vs 5% NRF cohort, _p_ = 0.008). Median OS and PFS were similar
between the two cohorts. Impaired renal function predicts for a higher rate of hospitalization, progression to dialysis and early mortality in patients receiving ASCT for AL amyloidosis.
Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this
journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now
Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer
support SIMILAR CONTENT BEING VIEWED BY OTHERS ACUTE KIDNEY INJURY DURING AUTOLOGOUS STEM CELL TRANSPLANTATION IN LIGHT CHAIN AMYLOIDOSIS WITH KIDNEY INVOLVEMENT AND THEIR IMPACT ON
PROGNOSIS Article 24 April 2024 OUTCOMES WITH EARLY VS. DEFERRED STEM CELL TRANSPLANTATION IN LIGHT CHAIN AMYLOIDOSIS Article 09 June 2020 OUTCOMES OF RENAL TRANSPLANTATION IN PATIENTS WITH
AL AMYLOIDOSIS: AN INTERNATIONAL COLLABORATION THROUGH THE INTERNATIONAL KIDNEY AND MONOCLONAL GAMMOPATHY RESEARCH GROUP Article Open access 18 August 2022 REFERENCES * Merlini G,
Dispenzieri A, Sanchorawala V, Schonland SO, Palladini G, Hawkins PN. et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4:38. Article Google Scholar *
Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho AD, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood.
2014;124:2325–32. Article CAS Google Scholar * Havasi A, Stern L, Lo S, Sun F, Sanchorawala V. Validation of new renal staging system in AL amyloidosis treated with high dose melphalan
and stem cell transplantation. Am J Hematol. 2016;91:E458–460. Article Google Scholar * Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ
involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22
April 2004. Am J Hematol. 2005;79:319–28. Article Google Scholar * Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in
immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30:4541–9. Article CAS Google Scholar
* Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light
chain measurements. J Clin Oncol. 2012;30:989–95. Article CAS Google Scholar * Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum cardiac troponins and
N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22:3751–7. Article CAS Google Scholar * Gertz MA, Lacy MQ, Dispenzieri A,
Hayman SR, Kumar SK, Dingli D, et al. Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leuk Lymphoma. 2010;51:2181–7. Article Google Scholar *
Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis.
Leukemia. 2012;26:2317–25. Article CAS Google Scholar * Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D, et al. Prognostic factors for survival and response after high-dose
therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol. 1998;101:766–9. Article CAS Google Scholar * Jaccard A, Moreau P,
Leblond V, Leleu X, Benboubker L, Hermine O, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007;357:1083–93. Article CAS Google Scholar
* Sidiqi MH, Aljama MA, Buadi FK, Warsame RM, Lacy MQ, Dispenzieri A, et al. Stem cell transplantation for light chain amyloidosis: decreased early mortality over Time. J Clin Oncol.
2018;36:1323–9. Article Google Scholar * D’Souza A, Dispenzieri A, Wirk B, Zhang MJ, Huang J, Gertz MA, et al. Improved outcomes after autologous hematopoietic cell transplantation for
light chain amyloidosis: A Center for International Blood and Marrow Transplant Research Study. J Clin Oncol. 2015;33:3741–9. Article Google Scholar * Gertz M, Lacy M, Dispenzieri A,
Hayman S, Kumar S, Buadi F, et al. Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leuk Lymphoma. 2008;49:36–41. Article CAS Google
Scholar * Lee SY, Meehan RS, Seldin DC, Sloan JM, Quillen K, Shelton A, et al. Effect of severe hypoalbuminemia on toxicity of high-dose melphalan and autologous stem cell transplantation
in patients with AL amyloidosis. Bone Marrow Transplant. 2016;51:1318–22. Article CAS Google Scholar Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Division of
Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN, USA M. Hasib Sidiqi, Kalyan Nadiminti, Abdullah S. Al Saleh, Kapil Meleveedu, Francis K. Buadi, Angela
Dispenzieri, Rahma Warsame, Martha Q. Lacy, David Dingli, Nelson Leung, Wilson I. Gonsalves, Prashant Kapoor, Taxiarchis V. Kourelis, William J. Hogan, Shaji K. Kumar & Morie A. Gertz *
Department of Hematology, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia Abdullah S. Al Saleh * Division of Nephrology, Department of Internal Medicine, Mayo
Clinic Rochester, Rochester, MN, USA Nelson Leung Authors * M. Hasib Sidiqi View author publications You can also search for this author inPubMed Google Scholar * Kalyan Nadiminti View
author publications You can also search for this author inPubMed Google Scholar * Abdullah S. Al Saleh View author publications You can also search for this author inPubMed Google Scholar *
Kapil Meleveedu View author publications You can also search for this author inPubMed Google Scholar * Francis K. Buadi View author publications You can also search for this author inPubMed
Google Scholar * Angela Dispenzieri View author publications You can also search for this author inPubMed Google Scholar * Rahma Warsame View author publications You can also search for this
author inPubMed Google Scholar * Martha Q. Lacy View author publications You can also search for this author inPubMed Google Scholar * David Dingli View author publications You can also
search for this author inPubMed Google Scholar * Nelson Leung View author publications You can also search for this author inPubMed Google Scholar * Wilson I. Gonsalves View author
publications You can also search for this author inPubMed Google Scholar * Prashant Kapoor View author publications You can also search for this author inPubMed Google Scholar * Taxiarchis
V. Kourelis View author publications You can also search for this author inPubMed Google Scholar * William J. Hogan View author publications You can also search for this author inPubMed
Google Scholar * Shaji K. Kumar View author publications You can also search for this author inPubMed Google Scholar * Morie A. Gertz View author publications You can also search for this
author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Morie A. Gertz. ETHICS DECLARATIONS CONFLICT OF INTEREST The authors declare that they have no conflict of interest.
ADDITIONAL INFORMATION PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. RIGHTS AND PERMISSIONS
Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Sidiqi, M.H., Nadiminti, K., Al Saleh, A.S. _et al._ Autologous stem cell transplantation in patients with AL amyloidosis with
impaired renal function. _Bone Marrow Transplant_ 54, 1775–1779 (2019). https://doi.org/10.1038/s41409-019-0524-2 Download citation * Received: 28 February 2019 * Revised: 19 March 2019 *
Accepted: 22 March 2019 * Published: 08 April 2019 * Issue Date: November 2019 * DOI: https://doi.org/10.1038/s41409-019-0524-2 SHARE THIS ARTICLE Anyone you share the following link with
will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt
content-sharing initiative